ABSTRACT. Disease-related prion protein (PrP Sc ), which is a structural isoform of the host-encoded cellular prion protein, is thought to be a causative agent of transmissible spongiform encephalopathies. However, the specific role of PrP Sc in prion pathogenesis and its relationship to infectivity remain controversial. A time-course study of prion-affected mice was conducted, which showed that the prion infectivity was not simply proportional to the amount of PrP Sc in the brain. Centrifugation (20,000 £g) of the brain homogenate showed that most of the PrP Sc was precipitated into the pellet, and the supernatant contained only a slight amount of PrP Sc . Interestingly, mice inoculated with the obtained supernatant showed incubation periods that were approximately 15 d longer than those of mice inoculated with the crude homogenate even though both inocula contained almost the same infectivity. Our results suggest that a small population of fine PrP Sc may be responsible for prion infectivity and that large, aggregated PrP Sc may contribute to determining prion disease duration.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative disorders, including scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease in cervids, and Creutzfeldt-Jakob disease in humans. Although the entity of the infectious agent, referred to as the prion, is still obscure, disease-related prion protein (PrP Sc ) is thought to be a main component of the causative agent of TSEs.
1,2 PrP Sc is generated by post-transcriptional modification of host cellular prion protein (PrP C ) and was originally defined by its proteinase K (PK) resistance and detergent insolubility. [3] [4] [5] PK resistance is a widely used property for discriminating between PrP Sc and PrP C , and this characteristic is critical for the diagnosis of prion diseases. Many studies have focused on the relationship between prion infectivity and PrP Sc , but the results have been conflicting. Some studies have demonstrated a reasonably close relationship between the amount of PrP Sc and prion infectivity, [6] [7] [8] whereas others have demonstrated that tissues or cells harboring high prion infectivity showed little or no detectable PrP Sc . [9] [10] [11] PrP Sc is currently believed to consist of multiple misfolded prion proteins, including proteasesensitive isoforms. [12] [13] [14] [15] [16] [17] PrP Sc also displays various aggregate sizes 18, 19 with the most infectious PrP Sc particles reported to be small aggregates approximately 17-27 nm in diameter. 20 More recently, 2 distinct PrP Sc populations were reported: one was associated with prion infectivity, and the other was associated with its neurotoxicity. 21 Thus, the role of PrP Sc in prion pathogenesis remains controversial.
In this study, the dynamics of PrP Sc and prion infectivity in mouse-adapted BSE (mBSE) were examined by immunohistochemistry, western blot analysis, enzyme-linked immunosorbent assay (ELISA), and endpoint titration assay to reveal the role of PrP Sc populations during prion disease progression.
RESULTS

No Involvement of PK-Sensitive PrP Sc in mBSE Prion Infectivity
To investigate the possibility that PK-sensitive PrP Sc contributes to prion infectivity, the mBSEbrain homogenate was first digested with 5, 40, and 100 mg/ml of PK and then the PrP Sc was detected by western blot. The samples were diluted to 1:100 with phosphate-buffered saline (PBS) and subjected to a bioassay to estimate their infectivity. As shown in Fig. 1 , the N-terminal truncated PK-resistant core of PrP Sc (PrP 27-30) was clearly detected, and no intact PrP Sc signal was detected from the samples digested with 5 and 40 mg/ml of PK. The incubation period of the mice inoculated with these samples was approximately 183 days, which was similar to that of mice inoculated with the undigested brain homogenate ( Table 1 ). In the sample digested with 100 mg/ml of PK, faint PrP Sc signals were detectable and the incubation period of the inoculated mice was extended to 254 § 3.3 d ( Table 1) . These results indicated that the prion infectivity of mBSE is not associated with PK-sensitive PrP Sc .
PrP Sc Accumulation in The Brain
The accumulation of PrP Sc was confirmed by immunohistochemistry in the vestibular nuclei at 40 d post-inoculation (dpi) in all of the mice examined (data not shown). There were clear PrP Sc deposits observed in the dorsal medulla at 70 dpi, but subtle or no spongiform changes were observed in the brain at this time point ( Fig. 2A-D) . The number of PrP Sc deposits increased, and moderate spongiform changes were observed in the dorsal medulla at 100 dpi ( Fig. 2E and F) . In addition, weak PrP Sc immunoreactivities were detected in the cerebral cortex, but there were few spongiform changes observed in the same region at 100 dpi Fig. 2G and H) . A large number of PrP Sc deposits and severe vacuolation in whole brain regions were observed at 140 dpi ( Fig. 2I-L) . These results indicate that neuropathological changes occurred after the accumulation of PrP Sc in the brain. In the western blot, PrP Sc was also detected at 40 dpi in all of the examined mice, and the amount of PrP Sc increased in accordance with the disease time course (Fig. 3) . ELISA was used for quantification of the dynamics of PrP Sc . This assay revealed that PrP Sc was amplified exponentially until the end of the disease with a doubling time of 12.4 d (Fig. 4 , blue dotted line), supporting the results of the western blot. The prion infectivity exponentially increased with a doubling time of 8.4 d (Fig. 4 , black solid line) until 100 dpi. The doubling time of infectivity was faster than that of PrP Sc at this disease stage. However, the prion infectivity reached a plateau at 100 dpi and was stable until the end of the disease (Fig. 4) . These results indicate a discrepancy between the replication rate of prion infectivity and PrP Sc accumulation. Therefore, to further examine the prion infectivity in small PrP Sc aggregates, the inoculum was centrifuged to remove the large aggregated PrP Sc .
Prion Titers and Incubation Periods of Brain Homogenates After Centrifugation
The brain homogenates of mBSE-affected mice were centrifuged at 20,000 £g for 10 min at 4 C, and the supernatant (20K-sup) was subjected Survival days of mice inoculated with 100 mg/mL PK-digested homogenates were significantly longer than those of the other groups (P < 0.001). ANOVA and a Tukey-HSD post-hoc test were used for statistical analysis (KaleidaGraph software program, Synergy Software, Reading, PA). Table 2 ). In spite of the decline of PrP Sc due to centrifugation, similar infectivity was restored in the 20K-sup. Interestingly, the incubation period of the 20K-sup was extended by approximately 15 d compared to that of the crude homogenate, even though both samples showed the same level of prion infectivity (Fig. 5B) . These results indicated that a small population of PrP Sc may contribute to the infectivity, whereas large, aggregated PrP Sc may play a role in accelerating the disease progression.
DISCUSSION
There are several reports suggesting that PKsensitive PrP Sc (PK-sen PrP Sc ) is responsible for prion infectivity. 12, 16, 17, 22 However, in the present study mBSE prion infectivity was not altered following digestion with 40 mg/mL of PK (Fig. 1) . Even with 5 mg/ml of PK digestion, the PrP Sc signal completely shifted to that of PrP27-30, which could indicate elimination of PK-sen PrP Sc . Although our results do not rule out the existence of PK-sen PrP Sc in mBSE, they do suggest that it has little or no contribution to mBSE prion infectivity. The involvement of PK-sensitive PrP Sc in prion infectivity may differ among prion strains.
We examined the PrP Sc dynamics in the mouse brain by immunohistochemistry, western blot, and ELISA, using basic criteria such as deposition or PK resistance. 23 Sc and infectivity to the end of diseases. [6] [7] [8] Our results demonstrated that the mBSE prion infectivity reached a plateau at 100 dpi, which supports the idea that prion infectivity is independent of the total amount of PrP Sc . We also examined the PrP Sc accumulation and spongiform changes in situ. As shown in Fig. 2 , few spongiform changes were observed at 100 dpi. However, the number of spongiform changes increased in the whole brain area after 100 dpi, and this period matched with the plateau infectivity stage. We propose that a portion of de novo synthesis of fine PrP Sc in brain cells may be associated with prion infectivity. In addition, polymerized and/ or elongated PrP Sc aggregation in neuropils at the late stage may be associated with neurotoxicity rather than prion infectivity. Acceleration of the production of toxic, large PrP Sc aggregates may be responsible for the plateau of prion infectivity. Indeed, it has been reported that 2 distinct types of PrP Sc isoforms may be involved in prion infectivity and neurotoxicity, respectively. 28 On the other hand, it is possible that the size of the infectious PrP Sc aggregates may differ among prion strains. 19 Variations in host species, prion strains, and the route of inoculation may also affect the amplification patterns of total PrP Sc and prion infectivity in the brain. These results highlight the importance of determining the size of aggregated PrP Sc to clarify prion pathogenesis. Therefore, the inoculum was simply centrifuged at 20,000 £g for 10 min at 4 C. With this process, most of the PrP Sc was precipitated into the pellet (97.7-99.6%), and a small population of PrP Sc remained in the supernatant (0.4-2.3%). We consider that the large PrP Sc aggregates and relatively fine PrP Sc aggregates could be separated with this simple centrifugation process. The end-point titration assay revealed that the 20K-sup and original homogenate harbored similar infectivity (10 8.4 vs. 10 8.6 LD 50 ). Several studies have supported the idea that infectious prions are comprised of a minority of PrP Sc , 9,10,28 and our data support this notion. Of particular note, the mice inoculated with the 20K-sup showed a delayed incubation period of approximately 15 d as compared to mice inoculated with the original homogenate with a similar titer (Fig. 5B) . The same phenomenon was observed in a previous study using an inoculum prepared from the spleens of prion-affected mice, which showed a longer incubation time than that prepared from brain samples containing the same infectious titer. 29 No large PrP Sc aggregates were observed in the spleen by immunohistochemistry, suggesting that the inoculum prepared from the spleen consisted of relatively fine PrP Sc aggregates, similar to the 20K-sup. Although the precise mechanism is obscure, our study suggests that large PrP Sc aggregates may act as a progression factor of prion disease. In addition, it has been reported that the detergent treatment of scrapie materials can lengthen the incubation period without reducing prion infectivity. 30, 31 Moreover, PMCA-generated PrP Sc , with an infectious dose comparable to that of the infected brain, has been reported to extend the disease incubation period. 32 Although we need to consider the involvement of cofactors, such as RNA molecules 33 and lipids, 34 in the infectivity and toxicity of PMCA-generated PrP Sc , these previous reports and our results suggest that the change of PrP Sc aggregate states has a big impact on prion pathogenicity, including infectivity and disease duration. Analyses of the associations of infectivity with the molecular size of PrP Sc aggregates are required to clarify the relationship between PrP Sc and its infectivity and toxicity. Furthermore, attention should be paid to the optimal sample conditions for comparing infectivity using an incubation time assay. Two distinct populations of PrP Sc isoforms were recently reported to be involved in prion infectivity and neurotoxicity, respectively. 28 Our results also imply the existence of 2 types of PrP Sc : one that is responsible for prion infectivity and the other that is associated with disease duration. However, it remains to be determined whether the 2 PrP Sc populations identified in this study are identical to those reported previously. Significant differences at P < 0.05 (*) in the survival days between mice inoculated with crude mBSE-BH and 20K-sup are indicated. I.U D infectious units (LD 50 per gram of the brain) calculated by Behrens-Karber's formula 28 .
In conclusion, we demonstrated that the 20K-sup contained highly infectious units in spite of only a small amount of PrP Sc . The incubation period of the 20K-sup was delayed by 15 d compared to that of the crude brain homogenate with the same prion titer. Further study is required to clarify the different types of PrP Sc and their role in prion pathogenesis.
MATERIALS AND METHODS
Animals and Prions
Mouse-adapted classical BSE (mBSE) prions, which had been passaged in ICR mice (Japan SLC, Hamamatsu, Japan) more than 10 times, were prepared from infected brains homogenized in PBS and intracerebrally inoculated into 3-week-old specific pathogen-free female ICR mice. The mice were examined daily and their survival periods were determined as the time from inoculation to the clinical endpoint or death. At appropriate times, the brain was collected and the left hemispheres were immediately stored at ¡80
C for the bioassay and biochemical analysis. The other hemispheres were fixed with 10% neutral-buffered formalin (pH 7.4) containing 10% methanol for histopathology.
All animal experiments were approved by the Animal Ethical Committee and the Animal Care and Use Committee of the National Institute of Animal Health (authorization 11-008 and 11-012). All experiments were conducted in biosafety level 3 facilities with strict adherence to safety protocols.
Prion Infectivity Assay
To determine the prion infectivity, an endpoint titration assay was conducted. The mouse brain homogenate was serially diluted with PBS, and then each dilution was intracerebrally inoculated into 5 or 6 ICR mice. Infectious units (LD 50 per gram of the brain) were determined according to Behrens-Karber's formula. 35 In some experiments, the brain homogenate was solubilized with 1% N-lauroylsarcosine (Sarkosyl, Sigma-Aldrich, Japan) and 1% n-dodecyl-b-D-maltoside (Dojindo Laboratories, Kumamoto, Japan) for 15 min at room temperature (R/T) and then digested with PK (Roche Diagnosis Japan, Tokyo, Japan) under the following conditions: 5 or 40 mg/ml at 37 C for 30 min, or 100 mg/ml at 37 C overnight. The samples were subjected to western blot for the detection of PrP Sc as described below. The aliquots of these samples were also diluted to 1:100 in PBS and then subjected to the incubation time assay 36 to compare the infectivity.
Time-Course Analysis of mBSE-Affected Mice
Twenty microliters of mBSE brain homogenates, which contained 10 5.9 LD 50 of mBSE, was intracerebrally inoculated into ICR mice. Four to 6 recipient mice were sacrificed at designated time points (dpi), and the brains were collected and examined.
ELISA
The ELISA method using the seprion ligand system (Microsens Biotechnologies, London, UK) was performed for the relative quantification of PrP Sc according to previously described protocols. 37, 38 ELISA plates were coated with a solution containing the seprion ligand (Microsens Biotechnologies, London, UK, 150 ml/ well) at R/T for 1 h and then blocked with 5% bovine serum albumin (BSA, 200 ml/well; Nacalai Tesque, Kyoto, Japan) at R/T for 30 min. Aliquots of the brain homogenate were lysed in 100 ml of lysis buffer (50 mM Tris-HCl [pH 8.3], 1% Sarkosyl, 1% Triton X-100, 1% BSA, 0.5 mg/ml trypsin) and then transferred to the seprion ligand-coated plates. After incubation at R/T for 2 h to allow PrP Sc isoforms to be captured on the seprion ligand, the plates were incubated with denaturation buffer (4 M guanidine hydrochloride, 20% polyethylene glycol 8000) at R/T for 10 min and then further incubated with horseradish peroxidase (HRP)-conjugated anti-PrP mAb T2 38 at 4 C for 2 h. Development was performed with a chemiluminescent substrate (Super Signal ELISA, Thermo Fisher Scientific, Rockland, IL) at R/T. The chemiluminescent signals were measured with a microplate reader (ARVO SV; PerkinElmer, Boston, MA). Two-fold serial dilutions of the mBSE-brain homogenate were subjected to ELISA to construct a standard curve for semiquantitative analysis of PrP Sc (Fig. S1 ).
Western Blot
Following PK digestion, the samples were mixed with an equal volume of a 2-butanol: methanol mixture (5:1), and PrP Sc was precipitated by 20,000 £g centrifugation. The pellets were resuspended in Laemmli sample buffer and boiled for 5 min. Samples were electrophoresed on NuPAGE Novex 12% Bis-Tris gels and NuPAGE MOPS-SDS running buffer in accordance with the manufacturer's instructions (Life Techonologies, Carlsbad, CA, USA). The proteins were transferred onto an Immobilon-P membrane (Millipore, Billerica, MA, USA). The blotted membrane was incubated with antiPrP monoclonal antibodies T2, 6H4 (Prionics, Zurich, Switzerland), and SAF84 (Bertin Pharma, Montigny le Bretonneux, France) at 4 C overnight. After washing with PBS containing Tween 20 twice, the membrane was incubated with HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA) for 60 min at R/T. Signals were developed with a chemiluminescent substrate (SuperSignal; Thermo Fisher Scientific). For semi-quantitation, blots were imaged using a Fluorchem system (Alpha Innotech, San Leandro, CA, USA) and analyzed using image reader software (AlphaEaseFC; Alpha Innotech) according to the manufacturer's instructions.
Histopathology and Immunohistochemistry
Formalin-fixed left hemispheres were immersed in 98% formic acid to reduce infectivity and then embedded in paraffin wax. Serial sections were stained with hematoxylin and eosin for evaluation of neuropathological changes. After epitope retrieval, PrP Sc immunocytochemistry was performed using the monoclonal antibody SAF84. Immunoreactions were developed using the anti-mouse universal immunoperoxidase polymer (Nichirei Histofine Simple Stain MAX-PO (M); Nichirei, Tokyo, Japan) as the secondary antibody and were visualized with 3,3 0 -diaminobenzedine tetrachloride as the chromogen.
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